Literature DB >> 33356812

Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer.

Urszula Dougherty1, Reba Mustafi1, Hongyan Zhu1, Xiaorong Zhu1, Dilip Deb1, Stephen C Meredith2, Fatma Ayaloglu-Butun1, Michelle Fletcher1, Arantxa Sanchez1, Joel Pekow1, Zifeng Deng1, Nader Amini1, Vani J Konda3, Vijaya L Rao1, Atsushi Sakuraba1, Akushika Kwesi1, Sonia S Kupfer1, Alessandro Fichera4, Loren Joseph5, John Hart2, Fang He6, Tong-Chuan He6, Diana West-Szymanski1, Yan Chun Li1, Marc Bissonnette1.   

Abstract

Because ADAM17 promotes colonic tumorigenesis, we investigated potential miRNAs regulating ADAM17; and examined effects of diet and tumorigenesis on these miRNAs. We also examined pre-miRNA processing and tumour suppressor roles of several of these miRNAs in experimental colon cancer. Using TargetScan, miR-145, miR-148a, and miR-152 were predicted to regulate ADAM17. miR-143 was also investigated as miR-143 and miR-145 are co-transcribed and associated with decreased tumour growth. HCT116 colon cancer cells (CCC) were co-transfected with predicted ADAM17-regulating miRNAs and luciferase reporters controlled by ADAM17-3'UTR. Separately, pre-miR-143 processing by colonic cells was measured. miRNAs were quantified by RT-PCR. Tumours were induced with AOM/DSS in WT and transgenic mice (Tg) expressing pre-miR-143/miR-145 under villin promoter. HCT116 transfection with miR-145, -148a or -152, but not scrambled miRNA inhibited ADAM17 expression and luciferase activity. The latter was suppressed by mutations in ADAM17-3'UTR. Lysates from colonocytes, but not CCC, processed pre-miR-143 and mixing experiments suggested CCC lacked a competency factor. Colonic miR-143, miR-145, miR-148a, and miR-152 were downregulated in tumours and more moderately by feeding mice a Western diet. Tg mice were resistant to DSS colitis and had significantly lower cancer incidence and tumour multiplicity. Tg expression blocked up-regulation of putative targets of miR-143 and miR-145, including ADAM17, K-Ras, XPO5, and SET. miR-145, miR-148a, and miR-152 directly suppress colonocyte ADAM17 and are down-regulated in colon cancer. This is the first direct demonstration of tumour suppressor roles for miR-143 and miR-145 in an in vivo model of colonic tumorigenesis.

Entities:  

Keywords:  DSS colitis; azoxymethane; colon cancer; miR-143/miR-145

Mesh:

Substances:

Year:  2020        PMID: 33356812      PMCID: PMC8813074          DOI: 10.1080/15592294.2020.1863117

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  75 in total

1.  The guideline of the design and validation of MiRNA mimics.

Authors:  Zhiguo Wang
Journal:  Methods Mol Biol       Date:  2011

2.  Expression of miR-224, miR-145, and their putative target ADAM17 in hepatocellular carcinoma.

Authors:  Yuwu Liu; Chang Wu; Ying Wang; Sailan Wen; Junpu Wang; Zhihong Chen; Qiongqiong He; Deyun Feng
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2014-06-26       Impact factor: 3.848

3.  miR-148a suppresses human renal cell carcinoma malignancy by targeting AKT2.

Authors:  Huiyan Cao; Zhiming Liu; Rong Wang; Xiaodong Zhang; Wenfa Yi; Guanyuan Nie; Yong Yu; Guolu Wang; Mingting Zhu
Journal:  Oncol Rep       Date:  2016-11-18       Impact factor: 3.906

4.  Exportin-5 Functions as an Oncogene and a Potential Therapeutic Target in Colorectal Cancer.

Authors:  Kunitoshi Shigeyasu; Yoshinaga Okugawa; Shusuke Toden; C Richard Boland; Ajay Goel
Journal:  Clin Cancer Res       Date:  2016-08-23       Impact factor: 12.531

5.  MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma.

Authors:  Ahmed Fawzy Ibrahim; Ulrike Weirauch; Maren Thomas; Arnold Grünweller; Roland K Hartmann; Achim Aigner
Journal:  Cancer Res       Date:  2011-06-20       Impact factor: 12.701

6.  The functional significance of microRNA-145 in prostate cancer.

Authors:  M S Zaman; Y Chen; G Deng; V Shahryari; S O Suh; S Saini; S Majid; J Liu; G Khatri; Y Tanaka; R Dahiya
Journal:  Br J Cancer       Date:  2010-06-29       Impact factor: 7.640

7.  Clinicopathologic study of dextran sulfate sodium experimental murine colitis.

Authors:  H S Cooper; S N Murthy; R S Shah; D J Sedergran
Journal:  Lab Invest       Date:  1993-08       Impact factor: 5.662

8.  ADAR mediates differential expression of polycistronic microRNAs.

Authors:  Geetanjali Chawla; Nicholas S Sokol
Journal:  Nucleic Acids Res       Date:  2014-02-20       Impact factor: 16.971

9.  Deciphering microRNA targets in pancreatic cancer using miRComb R package.

Authors:  Maria Vila-Casadesús; Elena Vila-Navarro; Giulia Raimondi; Cristina Fillat; Antoni Castells; Juan José Lozano; Meritxell Gironella
Journal:  Oncotarget       Date:  2018-01-08

10.  Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer.

Authors:  Charles Johannessen; Line Moi; Yury Kiselev; Mona Irene Pedersen; Stig Manfred Dalen; Tonje Braaten; Lill-Tove Busund
Journal:  PLoS One       Date:  2017-10-26       Impact factor: 3.240

View more
  3 in total

1.  Exploration of the Effect on Genome-Wide DNA Methylation by miR-143 Knock-Out in Mice Liver.

Authors:  Xingping Chen; Junyi Luo; Jie Liu; Ting Chen; Jiajie Sun; Yongliang Zhang; Qianyun Xi
Journal:  Int J Mol Sci       Date:  2021-12-03       Impact factor: 6.208

Review 2.  Impact of the Exposome on the Epigenome in Inflammatory Bowel Disease Patients and Animal Models.

Authors:  Sophie Vieujean; Bénédicte Caron; Vincent Haghnejad; Jean-Yves Jouzeau; Patrick Netter; Anne-Charlotte Heba; Ndeye Coumba Ndiaye; David Moulin; Guillermo Barreto; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Int J Mol Sci       Date:  2022-07-09       Impact factor: 6.208

Review 3.  MicroRNAs in Inflammatory Bowel Disease and Its Complications.

Authors:  Srikruthi S Krishnachaitanya; Max Liu; Ken Fujise; Qingjie Li
Journal:  Int J Mol Sci       Date:  2022-08-06       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.